These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 21417978)
1. What do we know about the ocular adverse effects associated with intravenous bisphosphonates? Atik OS Eklem Hastalik Cerrahisi; 2011; 22(1):1. PubMed ID: 21417978 [No Abstract] [Full Text] [Related]
2. A once-yearly IV bisphosphonate for osteoporosis. Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523 [No Abstract] [Full Text] [Related]
3. [Osteoporosis and bisphosphonates]. Zuber MA Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251 [No Abstract] [Full Text] [Related]
4. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis. Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098 [TBL] [Abstract][Full Text] [Related]
5. Annual zoledronic acid for osteoporosis. BMJ Group Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701 [TBL] [Abstract][Full Text] [Related]
6. A once-yearly IV bisphosphonate for osteoporosis. Obstet Gynecol; 2008 May; 111(5):1208-9. PubMed ID: 18448761 [No Abstract] [Full Text] [Related]
8. Consultation corner. Bone loss drug gives users a break. Bellantoni M Johns Hopkins Med Lett Health After 50; 2007 Dec; 19(10):6. PubMed ID: 18225340 [No Abstract] [Full Text] [Related]
9. Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update. Jimenez-Soriano Y; Bagan JV Med Oral Patol Oral Cir Bucal; 2005 Jul; 10 Suppl 2():E88-91. PubMed ID: 15995577 [No Abstract] [Full Text] [Related]
10. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?]. Ringe JD MMW Fortschr Med; 2009 Mar; 151(10):7. PubMed ID: 19472655 [No Abstract] [Full Text] [Related]
11. Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis. Med Lett Drugs Ther; 2009 Jun; 51(1315):49. PubMed ID: 19556940 [No Abstract] [Full Text] [Related]
12. Unilateral uveitis with vitreous haze following zoledronic Acid therapy for osteoporosis. Freitas-Neto CA; de Oliveira Fagundes WB; Ribeiro M; Pacheco KD; Freitas LG; Ávila MP Semin Ophthalmol; 2015 May; 30(3):232-4. PubMed ID: 24168214 [TBL] [Abstract][Full Text] [Related]
13. Respiratory complications associated with IV zoledronic acid infusion in the treatment of postmenopausal osteoporosis. Taggart H; Cheng J; Archbold P Osteoporos Int; 2010 Sep; 21(9):1621-2. PubMed ID: 19813042 [No Abstract] [Full Text] [Related]
14. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062 [TBL] [Abstract][Full Text] [Related]
15. Yearly zoledronic acid in postmenopausal osteoporosis. Chang JT N Engl J Med; 2007 Aug; 357(7):713-4; author reply 714-5. PubMed ID: 17703528 [No Abstract] [Full Text] [Related]
16. By the way, doctor. Should I take an intravenous drug for osteoporosis? Robb-Nicholson C Harv Womens Health Watch; 2007 Jul; 14(11):8. PubMed ID: 17665505 [No Abstract] [Full Text] [Related]
17. Going on a drug holiday? Bonnick SL J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091 [No Abstract] [Full Text] [Related]
18. Bisphosphonate-associated orbital inflammation--a case report and review. Peterson JD; Bedrossian EH Orbit; 2012 Apr; 31(2):119-23. PubMed ID: 22489855 [TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates: a once-yearly treatment option with Reclast. Van Gilder D S D Med; 2008 Nov; 61(11):416-7. PubMed ID: 19066136 [No Abstract] [Full Text] [Related] [Next] [New Search]